## Novel Human 12-Lipoxygenase (Lox) Inhibitors

Tech ID: 33578 / UC Case 2020-252-0

## BACKGROUND

Human Platelet-type 12-(S)-lipoxygenase (12-LOX) is a non-heme iron-containing oxygenase that catalyzes the regio- and stereo-specific addition of molecular oxygen to polyunsaturated fatty acids (PUFA). 12-LOX belongs to a family of enzymes that also include 5- LOX and 15-LOX, which oxygenate arachidonic acid (AA) at their corresponding carbon positions. The hydroperoxyeicosatetraenoic acid (HPETE) product is subsequently reduced by cellular peroxidases to form the hydroxyeicosatetraenoic acid (HETE), which in the case of 12- LOX is $12-(\mathrm{S})$-HETE.

Although 12-LOX expression is predominantly restricted to platelets ( $\sim 14,000$ molecules per platelet), it is also expressed in some hematopoietic and solid tumors. To date, 12-LOX is the only LOX isoform identified to be present in platelets, and its activity is part of a number of platelet functions, including granule secretion, platelet aggregation, and normal adhesion through specific agonist-mediated pathways, such as collagen and the thrombin receptor, PAR4. Normal platelet activation plays a central role in the regulation of hemostasis, but uncontrolled activation can lead to pathologic thrombotic events, such as ischemic coronary heart disease.

## TECHNOLOGY DESCRIPTION

Compounds of the structure are as provided below:

where R1, R2, R3, R4 and R5 are each independently selected from hydrogen, hydroxy, alkoxy, amine, cyano, thiol, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl,cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl; X is S or O; the $A$ ring is a substituted or unsubstituted 5 to 12 membered ring; $n$ is an integer from 0 to 12 ; and each $\mathrm{R}_{\mathrm{a}}$ is independently selected from hydrogen, hydroxy, alkoxy, amine, cyano, thiol, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or a salt, solvate or hydrate thereof.

## CONTACT

Jeff M. Jackson
jjackso6@ucsc.edu tel: .

## INTRODUCING

UC TechAlerts
New technology matches delivered to your email at your preferred schedule
Q SEARCH - © SAVE SEARCH

## Learn More

## INVENTORS

- Holman, Theodore R.
- Jacobson, Matthew
- Nadler, Jerry


## OTHER INFORMATION

## CATEGORIZED AS

- Medical

Disease: Cardiovascular
and Circulatory System
$>$ Therapeutics

RELATED CASES
2020-252-0, 2021-597-0, 2021-934-

0, 2022-800-0

The predicted binding mode of Compound LOX-12-001 with wt12-LOX is shown below. Residues that interact with the inhibitor are shown. Residues that mutated in the present study are shown in ball-andstick representation and they are labelled.


## APPLICATIONS

- Treating or preventing an immune-mediated thrombocytopenia or thrombosis disorder.
- Treating diabetes, type II diabetes, diabetic kidney disease, diabetic nerve disease, cardiovascular disease, non-alcoholic steatohepatitis, platelet hemostasis, heparin-induced thrombocytopenia, thrombosis, Alzheimer's disease and cancer.


## ADVANTAGES

Greater specificity and better solubility than other 12-LOX inhbitors.

INTELLECTUAL PROPERTY INFORMATION

| Country | Type | Number |
| :--- | :--- | :--- |
| European Patent Office | Published Application | Dated |
| Canada | Published Application | $2020-252$ |
| China | Published Application | $2021-597$ |
| European Patent Office | Published Application | $2021-597$ |
| Israel | Published Application | $2021-597$ |
| India | Published Application | $2021-597$ |
| Japan | Published Application |  |
| Republic Of Korea (South Korea) | Published Application |  |
| European Patent Office | Published Application | WO 2024/019959 |


| Patent Cooperation Treaty | Reference for National Filings | WO 2023/019090 | $02 / 16 / 2023$ | $2021-597$ |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Patent Cooperation Treaty | Reference for National Filings | WO 2023/009347 | $02 / 02 / 2023$ | $2021-934$ |
| Patent Cooperation Treaty | Reference for National Filings | WO 2022/236086 | $11 / 10 / 2022$ | $2020-252$ |

Additional Patents Pending

## RELATED MATERIALS

Docking and mutagenesis studies lead to improved inhibitor development of ML355 for human platelet 12-lipoxygenase - 09/15/2021

## RELATED TECHNOLOGIES

- ML351 As Treatment For Stroke And Ischemic Brain Injury
- 15LOX1 Inhibitor Formulation Determination For IV Administration
> COMPOUNDS FOR MODULATING EPITHELIAL 15-(S)-LIPOXYGENASE-2 AND METHODS OF USE FOR SAME

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- COMPOUNDS FOR MODULATING EPITHELIAL 15-(S)-LIPOXYGENASE-2 AND METHODS OF USE FOR SAME
- ML351 As Treatment For Stroke And Ischemic Brain Injury
- 15LOX1 Inhibitor Formulation Determination For IV Administration
- 15Lox1 Inhibitors For Stroke

Industry Alliances \& Technology Commercialization
Kerr 413 / IATC,
Santa Cruz,CA 95064

